Castration-resistant Prostate Cancer
📧 Sign up to get email alerts when something new happens for Castration-resistant Prostate Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS withdrawal · 2026-03-31Clinical Trial Update: A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3720 Tablets [Phase 1]
Phase 1 study evaluating TQB3720 tablets for metastatic castration-resistant prostate cancer has been terminated.
-
CLINICAL_TRIALS withdrawal · 2025-09-29Clinical Trial Update: Race Impact on Efficacy of Niraparib Plus Abiraterone Acetate and Prednisone in Patients With Homologous Repair Deficient Castration-resistant Prostate Cancer [Phase 2]
Phase 2 trial assessing race-related differences in the efficacy of niraparib plus abiraterone acetate and prednisone in homologous recombin…
-
CLINICAL_TRIALS withdrawal · 2025-03-12Clinical Trial Update: Real-life Experience in Brazil in Patients With Castration-resistant Prostate Cancer Treated With Olaparib+Abiraterone
Clinical trial update reports real-world Brazilian experience in castration-resistant prostate cancer patients treated with the combination …
-
CLINICAL_TRIALS withdrawal · 2025-02-03Clinical Trial Update: A Prospective Compliance Registry for Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
A clinical trial registry entry for Janssen's prospective compliance registry in metastatic castration-resistant prostate cancer has been wi…
-
CLINICAL_TRIALS withdrawal · 2025-02-03Clinical Trial Update: A Post-marketing Surveillance to Assess Safety of Abiraterone Acetate (Zytiga) in Indian Participants With Metastatic, Castration Resistant Prostate Cancer
A post-marketing safety study of abiraterone acetate (Zytiga) in Indian participants with metastatic castration-resistant prostate cancer ha…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS withdrawal · 2024-09-19Clinical Trial Update: 177Lu-PSMA, Niraparib/AA Plus Prednisone for Prostate Cancer [Phase 1, Phase 2]
A Phase 1/2 trial evaluating 177Lu-PSMA-617 with Niraparib and abiraterone acetate plus prednisone for metastatic prostate cancer and castra…
-
CLINICAL_TRIALS withdrawal · 2024-08-19Clinical Trial Update: HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC) [Phase 3]
Phase 3 trial HC-1119 versus enzalutamide for metastatic castration-resistant prostate cancer has been terminated; no results are provided i…
-
CLINICAL_TRIALS withdrawal · 2024-05-02Clinical Trial Update: Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations [Phase 1]
A Phase 1 trial evaluating the addition of magrolimab to olaparib for BRCA-mutated metastatic breast cancer or castration-resistant prostate…
-
CLINICAL_TRIALS withdrawal · 2023-09-14Clinical Trial Update: Darolutamide With Radium-223 or Placebo and the Effect on Radiological Progression-Free Survival for Patients With mCSPC [Phase 3]
Phase 3 trial investigating darolutamide with radium-223 or placebo in metastatic castration-resistant prostate cancer was withdrawn.
-
CLINICAL_TRIALS withdrawal · 2023-08-04Clinical Trial Update: Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)-China Extension [Phase 3]
Phase 3 trial (KEYNOTE-921) evaluating pembrolizumab with docetaxel versus placebo with docetaxel in chemotherapy-naïve metastatic castratio…
-
CLINICAL_TRIALS withdrawal · 2018-07-30Clinical Trial Update: Orteronel Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents [Phase 3]
Phase 3 trial evaluating Orteronel as maintenance therapy in metastatic castration-resistant prostate cancer previously treated with novel h…
-
CLINICAL_TRIALS withdrawal · 2018-03-12Clinical Trial Update: Efficacy and Safety Study of LE-DT to Treat Metastatic Castrate Resistant Prostate Cancer [Phase 2]
A Phase 2 trial evaluating LE-DT for metastatic castration-resistant prostate cancer has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2018-03-01Clinical Trial Update: Safety and Anti-Tumor Study of Oral EPI-506 for Patients With Metastatic Castration-Resistant Prostate Cancer [Phase 1, Phase 2]
Phase 1/2 trial of EPI-506 for metastatic castration-resistant prostate cancer has been terminated.
-
CLINICAL_TRIALS withdrawal · 2017-10-30Clinical Trial Update: Provenge Followed by Docetaxel in Castration-Resistant Prostate Cancer [Phase 2]
A Phase 2 trial evaluating sipuleucel-T (Provenge) followed by docetaxel in castration-resistant prostate cancer has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2016-11-22Clinical Trial Update: A Study of the Clinical Activity and Safety of JNJ-64041809, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Apalutamide Versus Apalutamide in Subjects With Metastatic Castration-resistant Prostate Cancer [Phase 2]
A Phase 2 study evaluating JNJ-64041809 in combination with apalutamide versus apalutamide for metastatic castration-resistant prostate canc…
-
CLINICAL_TRIALS withdrawal · 2016-10-12Clinical Trial Update: A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC) [Phase 3]
A Phase 3 trial evaluating custirsen added to docetaxel retreatment or cabazitaxel as second-line therapy for metastatic castration-resistan…
-
CLINICAL_TRIALS withdrawal · 2016-08-31Clinical Trial Update: Carbon-11 Acetate and Fluorine F 18 Sodium Fluoride PET as a Biomarker of Treatment Response in Patients With Hormone Resistant Metastatic Prostate Cancer [NA]
The clinical trial using PET tracers carbon-11 acetate and fluorine-18 sodium fluoride to assess treatment response in hormone-resistant met…
-
CLINICAL_TRIALS withdrawal · 2016-08-17Clinical Trial Update: Cabazitaxel in mCRPC Patients With AR-V7 Positive CTCs [Phase 2]
A Phase 2 trial evaluating cabazitaxel in metastatic castration-resistant prostate cancer patients with AR-V7 positive circulating tumor cel…
-
CLINICAL_TRIALS withdrawal · 2016-08-12Clinical Trial Update: A Study to Assess the Effects of MK0822 in Prolonging Time to First Bone Metastasis in Men With Castration-Resistant Prostate Cancer (0822-030) [Phase 3]
A Phase 3 trial evaluating MK0822 for prolonging time to first bone metastasis in men with castration-resistant prostate cancer has been wit…
-
CLINICAL_TRIALS withdrawal · 2016-06-10Clinical Trial Update: TAK-700 in Castration Resistant Prostate Cancer [Phase 2]
A Phase 2 trial of TAK-700 (orteronel) for castration-resistant prostate cancer has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2016-02-11Clinical Trial Update: Cabazitaxel and BKM120 in Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel [Phase 2]
A Phase 2 trial of cabazitaxel plus buparlisib for metastatic castration-resistant prostate cancer previously treated with docetaxel has bee…
-
CLINICAL_TRIALS withdrawal · 2016-02-11Clinical Trial Update: Exercise Intervention for Pts With Metastatic Castration-Resistant Prostate Cancer Receiving Abiraterone or Enzalutamide [NA]
A clinical trial evaluating an exercise intervention for patients with metastatic castration-resistant prostate cancer receiving abiraterone…
-
CLINICAL_TRIALS withdrawal · 2015-12-02Clinical Trial Update: Post-marketing Surveillance Study on the Safety and Effectiveness of Abiraterone Acetate Among Adult Filipino Male Patients With Advanced Metastatic Castration Resistant Prostate Cancer
A post-marketing surveillance study evaluating the safety and effectiveness of abiraterone acetate in adult Filipino men with advanced metas…
-
CLINICAL_TRIALS withdrawal · 2015-11-20Clinical Trial Update: A Study of Radium-223 in Combination With Tasquinimod in Bone-only Metastatic Castration-Resistant Prostate Cancer [Phase 1]
A Phase 1 trial evaluating the combination of radium-223 dichloride with tasquinimod for bone-only metastatic castration-resistant prostate …
-
CLINICAL_TRIALS withdrawal · 2015-10-27Clinical Trial Update: A Phase 1b Dose Escalation Trial of PSK®/Placebo With Docetaxel to Treat Metastatic Castration-resistant Prostate Cancer [Phase 1]
A Phase 1b dose-escalation study of PSK with docetaxel for metastatic castration-resistant prostate cancer has been withdrawn.